FDA cited Pro Numb Tattoo Numbing Spray for selling unapproved, misbranded numbing drugs and manufacturing quality failures after a November 2025 inspection.
What happened
FDA inspected the Palm Bay, FL drug manufacturing facility from November 5 to 6, 2025, and reviewed the company’s November 13, 2025 response to the Form FDA 483 (inspection observations). FDA found failures in current good manufacturing practice (CGMP), including no finished-product release testing, no identity testing of incoming ingredients, stability data recorded without testing, no process validation, and an inadequate quality unit. FDA also found that labels and the website make drug claims for numbing sprays, making them unapproved new drugs and misbranded.
What FDA found
The company released drug batches without finished-product laboratory testing for identity, strength, quality, and purity.
21 CFR 211.165(a)The company did not test incoming ingredients, including active ingredients, for identity and did not verify suppliers’ test reports; it also lacked adequate testing of an incoming component for microbial limits.
21 CFR 211.84(d)(1) and (d)(2)The company’s stability program was inadequate, and staff recorded microbial results without performing tests and left assay results blank.
21 CFR 211.166(a)The company did not validate its manufacturing processes or establish adequate controls for fill volume and viscosity, including judging viscosity by looking at the product.
21 CFR 211.100(a)The quality unit lacked authority and failed to ensure batch records, training, equipment calibration, and storage monitoring were adequate.
21 CFR 211.22The numbing sprays are unapproved new drugs and misbranded because their labels and website make drug claims, such as pain relief, without FDA approval.
FD&C Act 505(a), 301(d), 502(ee), 301(a); 21 U.S.C. 355(a), 331(d), 352(ee), 331(a)
What FDA wants
FDA tells the company to provide comprehensive independent assessments, corrective action plans, test methods and specifications, supplier and lab qualification details, stability and process validation plans, and evidence of an effective quality unit. The letter does not state a response deadline.
Who should pay attention
- companies selling OTC topical analgesics
- contract labs and ingredient suppliers for drug manufacturers
- retailers and distributors of tattoo-care numbing products
This is a summary. Read the original letter on fda.gov.